Recordati stock holds just above EUR 52 as investors digest the latest earnings and valuation
Published on 08/22/2026 at 10:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Recordati S.p.A. (ISIN IT0003828271) stock is trading at EUR 52.78 per share as of the latest completed Milan session on August 21, 2026, leaving the shares modestly up year to date and close to recent short-term resistance levels.
Share price and market context
Per a recent market overview, Recordati closed the session at EUR 52.78 on August 21, 2026, with a 0.19 percent gain over the prior session and a 0.29 percent increase over the past five trading days, while the year-to-date performance stands at 8.52 percent in positive territory. This market snapshot shows the stock consolidating in the low-50s euro range after recent moves.
A separate capitalization ranking of Italian equities lists Recordati with a market capitalization of EUR 10,832 million, positioning the group among the larger mid-cap names on Piazza Affari and reinforcing its relevance in the European healthcare sector. The capitalization table underscores that Recordati is competing for investor attention against banks and other large domestic issuers.
Earnings, operations and valuation
Recent half-year results for 2026, referenced in the latest coverage and investor materials, indicate that Recordati continues to generate solid revenue and earnings in its core prescription pharmaceuticals and rare diseases franchises, with the most recent reporting period supporting a positive year-to-date share performance. The reported figures show growth in key therapeutic segments compared with the previous year, while operating profitability remains a central focus for management and investors.
For context, Recordati has historically reported rising revenue and earnings up to fiscal 2023, when the company delivered higher sales and net profit versus the prior fiscal year. This historical baseline now serves as a comparison point for the 2026 interim results, which investors use to gauge whether the growth trajectory in prescription medicines and specialty products is continuing at a sustainable pace.
On the valuation side, the EUR 10,832 million market capitalization places Recordati at a premium to many smaller Italian healthcare names but still at a discount to larger global pharmaceutical players, suggesting that the shares are priced to reflect a mix of mature cash-generating assets and growth options in rare diseases. As the company reports each new quarter, the balance between dividend income, reinvestment in R&D and bolt-on acquisitions remains central to how the market values the stock.
Recordati Rare Diseases product focus
Beyond its mainstream prescription portfolio, Recordati operates a dedicated rare diseases division that markets specialized therapies to small patient populations through Recordati Rare Diseases Inc., a US-based subsidiary. A national drug code listing identifies Recordati Rare Diseases Inc. as a labeler of rare disease medicines in the United States, highlighting the group’s presence in this niche but strategically important market.
These rare disease therapies, which often target metabolic, genetic or other hard-to-treat conditions, typically command higher pricing and require close engagement with specialist physicians and patient advocacy groups. For investors, this business segment can contribute to margins and growth potential that differ from more competitive, commoditized pharmaceutical categories, although development and regulatory risks are also higher for such targeted treatments.
Stock level and investor view
As of the latest completed trading session on August 21, 2026, Recordati shares trade at EUR 52.78 on their home Italian exchange, supported by a market capitalization of EUR 10,832 million and a positive year-to-date performance of 8.52 percent that reflects steady investor confidence in the company’s earnings and rare diseases strategy.
Fact box
Company: Recordati S.p.A.
ISIN: IT0003828271
Ticker: REC
Exchange: Borsa Italiana (Milan)
Price (as of August 21, 2026, 11:30 a.m. ET): EUR 52.78
Market cap: EUR 10,832 million (as of August 21, 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: FTSE Mid Cap Italy
